Drug Profile
Research programme: K-ras oncogenes inhibitors - Astellas/Dana-Farber Cancer Institute
Latest Information Update: 28 Dec 2018
Price :
$50
*
At a glance
- Originator Dana-Farber Cancer Institute
- Developer Astellas Pharma; Dana-Farber Cancer Institute
- Class Small molecules
- Mechanism of Action Ras gene inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for research development in Cancer in USA
- 04 Nov 2014 Early research in Cancer in USA (unspecified route)